Abstract
At present cancer treatment is still a confusing problem. Great progress has been made in anti-tumor agents since a series of small molecules are approved by FDA as anti-tumor drugs. Nitroimidazoles is a kind of radiosensitizer with multiple bioactivities used in cancer treatment since 1950s. In this review, we focus on the development of nitroimidazoles as radiosensitizer, bio-reductive prodrug and other types of anti-tumor agents for cancer therapy, and the mechanism of acting as anti-tumor agents. Finally, we also discuss the prospect and developmental trend of nitroimidazoles as anti-tumor agents.
Keywords: Anti-tumor, 2-Nitroimidazole, Hypoxic cell radiosensitizer, Bio-reductive prodrug, Abl tyrosine kinase inhibitor, nitroimidazoles, synergistic effect, normoxia, chemotherapy
Anti-Cancer Agents in Medicinal Chemistry
Title: Nitroimidazoles as Anti-Tumor Agents
Volume: 11 Issue: 7
Author(s): Kai Liu and Hai-Liang Zhu
Affiliation:
Keywords: Anti-tumor, 2-Nitroimidazole, Hypoxic cell radiosensitizer, Bio-reductive prodrug, Abl tyrosine kinase inhibitor, nitroimidazoles, synergistic effect, normoxia, chemotherapy
Abstract: At present cancer treatment is still a confusing problem. Great progress has been made in anti-tumor agents since a series of small molecules are approved by FDA as anti-tumor drugs. Nitroimidazoles is a kind of radiosensitizer with multiple bioactivities used in cancer treatment since 1950s. In this review, we focus on the development of nitroimidazoles as radiosensitizer, bio-reductive prodrug and other types of anti-tumor agents for cancer therapy, and the mechanism of acting as anti-tumor agents. Finally, we also discuss the prospect and developmental trend of nitroimidazoles as anti-tumor agents.
Export Options
About this article
Cite this article as:
Liu Kai and Zhu Hai-Liang, Nitroimidazoles as Anti-Tumor Agents, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (7) . https://dx.doi.org/10.2174/187152011796817664
DOI https://dx.doi.org/10.2174/187152011796817664 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Origins, Structures, and Bioactivities of Secondary Metabolites from Marine-derived Penicillium Fungi
Mini-Reviews in Medicinal Chemistry Indoleamine 2,3-Dioxygenase, an Emerging Target for Anti-Cancer Therapy
Current Cancer Drug Targets Harnessing the Prevention Benefits of Antiretroviral Therapy to Address HIV and Tuberculosis
Current HIV Research Good, Bad, Mobile Elements: Genome’s Most Successful “Parasites” as Emerging Players in Cell and Organismal Aging
Current Pharmaceutical Design Oxidative Stress Based-Biomarkers in Oral Carcinogenesis: How Far Have We Gone?
Current Molecular Medicine Context-dependent Action of Transforming Growth Factor β Family Members on Normal and Cancer Stem Cells
Current Pharmaceutical Design Nanoparticle-Delivered Quercetin for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Nutrition, Nitrogen Requirements, Exercise and Chemotherapy-Induced Toxicity in Cancer Patients. A puzzle of Contrasting Truths?
Anti-Cancer Agents in Medicinal Chemistry Interview with Dr. Young-Ki Paik, President of the Human Proteome Organization (HUPO): Pharmacoproteomics and the Approaching Wave of “Proteomics Diagnostics”
Current Pharmacogenomics and Personalized Medicine Synthesis, Anticancer Evaluation and Docking Study of 3- Benzyloxyhydantoin Derivatives
Medicinal Chemistry DNA Damage Response Pathways and Cell Cycle Checkpoints in Colorectal Cancer: Current Concepts and Future Perspectives for Targeted Treatment
Current Cancer Drug Targets UPA and PAI-1 Analysis from Fixed Tissues – New Perspectives for a Known Set of Predictive Markers
Current Medicinal Chemistry Personalized Medicine in a Consumer Age
Current Pharmacogenomics and Personalized Medicine Current Targets for Anticancer Drug Discovery
Current Drug Targets Should the Status of the Pathway Mediated by BRCA1 and BRCA2 be Evaluated Before Selecting Cancer Chemotherapy Drugs?
Current Pharmacogenomics Macromolecular Prodrugs Based on Synthetic Polyaminoacids: Drug Delivery and Drug Targeting in Antitumor Therapy
Current Topics in Medicinal Chemistry 3D QSAR of Aminophenyl Benzamide Derivatives as Histone Deacetylase Inhibitors
Medicinal Chemistry Blending of Polyethylenimine with a Cationic Polyurethane Greatly Enhances Both DNA Delivery Efficacy and Reduces the Overall Cytotoxicity
Current Pharmaceutical Biotechnology The Promise of miRNA Replacement Therapy for Hepatocellular Carcinoma
Current Gene Therapy Chemical Origins of Isoform Selectivity in Histone Deacetylase Inhibitors
Current Pharmaceutical Design